Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model.
This demonstration marks a significant step for Lantern as it transitions withZeta.ai from an internal tool to a commercially available product. The platform, now available as a subscription-based research platform for the global biomedical and drug development community, represents a new revenue stream for the company, according to the press release. By offering live public access, Lantern aims to illustrate the platform’s capabilities in real-time, potentially attracting subscribers from academic institutions, biotech firms, and pharmaceutical companies.
The withZeta.ai platform is a multi-agentic AI co-scientist that leverages Lantern’s proprietary RADR® platform and machine learning to analyze vast datasets. Its ability to integrate clinical, molecular, and scientific information could shorten the time required to identify drug candidates and optimize clinical trials, particularly in rare cancers where traditional approaches are often slow and costly. Lantern’s pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The announcement comes as artificial intelligence continues to reshape drug discovery, with companies increasingly turning to AI to reduce costs and improve success rates. Lantern’s move to commercialize withZeta.ai could position it to compete with other AI-driven biotech platforms, though the company must demonstrate tangible value to potential subscribers. The live demo on April 30 will be a key test of the platform’s capabilities and its ability to attract a customer base.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The full press release is available at https://ibn.fm/wzevl. For more information about Lantern and its pipeline, visit the company’s newsroom at https://ibn.fm/LTRN.
